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Recently,  3D  printing  as  effective  technology  has  been  highlighted  in  the  biomedical  ﬁeld.  Previously,  a
porous  hydroxyapatite  (HA)  scaffold  with  the biocompatibility  and  osteoconductivity  has  been developed
by  this  method.  However,  its osteoinductivity  is limited.  The  main  purpose  of this  study  was  to  improve
it  by  the introduction  of  recombinant  human  bone  morphogenetic  protein-2  (rhBMP-2).  This  scaffold
was  developed  by  coating  rhBMP-2-delivery  microspheres  with  collagen.  These  synthesized  scaffolds
were  characterized  by  Scanning  Electron  Microscopy  (SEM),  a delivery  test  in vitro,  cell  culture,  and
the experiments  in vivo by  a  Micro-computed  tomography  (CT)  scan  and  histological  evaluation  of
VanGieson  staining.  SEM results  indicated  the surface  of  scaffolds  were  more  ﬁt for the  adhesion  of
hMSCs  to  coat  collagen/rhBMP-2  microspheres.  Biphasic  release  of  rhBMP-2  could  continue  for  moreontrolled release
steogenic effect
than  21 days,  and  keep  its osteoinductivity  to induce  osteogenic  differentiation  of hMSCs  in vitro. In
addition,  the  experiments  in  vivo  showed  that  the  scaffold  had  a good  bone  regeneration  capacity.  These
ﬁndings  demonstrate  that the  HA/Collagen/Chitosan  Microspheres  system  can  simultaneously  achieve
localized  long-term  controlled  release  of  rhBMP-2  and  bone  regeneration,  which  provides  a  promising
reatm
ublisroute  for  improving  the t
©  2016  The  Authors.  P
. Introduction
Repairing critical bone defects due to trauma, tumors, infection
nd so on, is still a major challenge for orthopedists. The application
f autografts and allografts are restricted in clinics because of the
imited supply, complications of donor site, and the risk of disease
ransmission [1,2]. Thus, tissue engineered bone (TEB) has drawn
ore and more attention as an alternative [3].
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/).ent  of bone  defects.
hed  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
With the advantage of the controlled inner/outer architec-
ture, pores, porosity, and interconnectivity, 3D printed scaffolds
are becoming of increasing interest compared to traditional ones
[3]. Vessels and nerves can easily grow into the scaffold for the
integration of channels [4]. They have a remarkable potential for
bone formation and healing [5,6]. Some of them, including a poly-
caprolactone (PCL) scaffold (Osteopore International Pte) and a
polymethyl-methacrylate scaffold (OXPEKK-IG OsteoFab; Oxford
Performance Materials), have been approved for commercial pro-
duction by the Food and Drug Administration (FDA) [7,8]. Rapid
prototyping (RP) technology (one of 3D printing technologies) is a
good choice for fabricating TEB scaffolds due to its reliability and
its reproducibility [9]. Polymer/ceramic composite scaffolds fab-
ricated by RP techniques show enhanced mechanical properties
and biocompatibility [10–12]. The stoichiometry of hydroxyap-
atite(HA) is similar to the inorganic part of natural bone, so it is
a promising TEB [13]. In our previous studies, a new porous HA
ceramic scaffold has been fabricated by the micro-syringe extrusion
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ystem, a RP technique [14]. Its biocompatibility and osteocon-
uctivity have been conﬁrmed before, but the osteoinductivity is
till limited [14,15]. Thus, it’s very important to functionalize this
caffold to accelerate the bone healing process.
Bone morphogenetic proteins(BMPs), members of the trans-
orming growth factor beta (TGF-ß) superfamily, have osteoin-
uctive property, and two of them (BMP-2 & BMP-7) are widely
vailable commercially [16]. Speciﬁcally, BMP-2 shows a very
trong osteoinductive activity [17]. Thus, the introduction of
ecombinant human bone morphogenetic protein-2 (rhBMP-2) to
his HA scaffold could potentially enhance its osteoinductivity. But,
hBMP-2 alone cannot induce bone regeneration because of its
hort retention [18]. A collagen sponge is suggested for rhBMP-2 by
he manufacturer. Adverse effects may  rise at an excessively high
ose, which is aimed to overcome its rapid diffusion [19]. Long-
erm delivery of rhBMP-2 could enhance the osteogenic efﬁcacy
s compared with the short-term delivery [20]. A suitable deliv-
ry system of rhBMP-2 plays a key role to ensure its controlled
elease and the bioactivity. Previously, we have prepared chitosan
icrospheres (CMs) containing encapsulated BMP-2 or synthetic
eptide derived from BMP-2 [21,22]. Through the introduction of
Ms  loaded with BMP-2 and BMP-2-derived synthetic peptide, the
omposite could induce obvious ectopic bone formation.
In this study, we hypothesized that the introduction of rhBMP-
 through CMs  can provide the 3D printed porous HA scaffold
ith the osteoinductivity. To test it, a porous HA scaffold fabri-
ated by RP technique was coated with rhBMP-2CMs by collagen.
e  demonstrate that controlled release of rhBMP-2 could induce
uman Mesenchymal Stem Cells (hMSCs) for osteogenic differen-
iation in vitro and ectopic bone formation in vivo.
. Materials and methods
.1. Materials
HA powder (MH-HAP) was obtained from Nanjing Emperor
ano Material Co., Ltd., China. rhBMP-2 was obtained from
edtronic, Inc., USA. Type I collagen (C9879), 1-ethyl-3-[3-
imethylaminopropyl] carbodiimide hydrochloride (EDC), N-
ydroxysuccinimide (NHS), and chitosan were purchased from
igma-Aldrich Co., USA.
.2. Fabrication of porous HA scaffolds
The elliptic cylindrical porous HA scaffold of 15 × 7 × 5 mm3
ith 500 m pores was prepared as previously described [14].
rieﬂy, the speciﬁcations of the scaffold were predeﬁned using the
xtrusion deposition system (MAM-II, Fochif, China). 30vol% HA
lurry extruded from the conical nozzle and constructed in a layer
y layer process under the control of computer. The scaffolds were
ir dried for 24 h at room temperature after the construction was
ompleted. Then, the scaffolds were sintered in a 1.4 kW,  2.45 GHz
icrowave furnace (Hamilab-V1500, Syno-therm. Co. Ltd., China)
sing the following procedure: temperature increased to 400 ◦C
lowly (2 ◦C/min) for 1 h at ﬁrst, then increased to 1200 ◦C rapidly
or 30 min  to improve the strength of the scaffold, and at last, cooled
o room temperature.
.3. Preparation of CMs  containing rhBMP-2
CMs  containing rhBMP-2 were prepared with the emulsion
ross-linking method as previously described [21,22]. Brieﬂy, 3%
w/v) span, 2.4% (w/v) tween and 3% (w/v) magnesium stearate
ere dissolved in liquid parafﬁn to obtain the oil phase. And the
bove mixture was stirred at 45 ◦C using water bath for 1 h. 450 mg
hitosan and 4 mg  rhBMP-2 was dispersed in 2% (V/V) aqueousBiointerfaces 141 (2016) 491–498
acetic acid solution and agitated for 30 min. Thereafter, the chitosan
solution was  dropped into the liquid parafﬁn slowly. One  gram of 3-
methoxy-4-hydroxybenzaldehyde (vanilline) was  dissolved in 2 ml
alcohol and added to the W/O  emulsion. The emulsion was stirred
for 6 h. The obtained microspheres were washed with petroleum
ether and isopropanol to remove the remaining solvent, and then
lyophilized for 18 h.
2.4. Synthesis of scaffolds coated with collagen/CMs
Collagen I was dissolved in acetic acid (0.05 M) to obtain a con-
centration of 0.1 g/ml. The sterilized HA scaffolds were soaked in
the collagen solution and put in a vacuum drying oven for vacuum
aspiration for 24 h. First, both EDC and NHS were added in MES-
buffered solution (pH 5.5) with a EDC:NHS ratio of 4:1 (w/w). Then,
the solution with 2.5 mg/ml  EDC and 0.63 mg/ml  NHS was added
to the collagen solution to cross-link the collagen. After incubating
for 4 h, the HA/Collagen scaffolds were dried at 37 ◦C for 6 h. There-
after, the HA/Collagen (HC) scaffolds were washed with phosphate
buffer solution (PBS, pH 7.4, Gibco inc., USA). The coating process
was performed under sterilized condition.
The synthesis of HA scaffold coated with collagen/rhBMP-2CMs
(HCC) was  prepared using a previously described post-seeding
technique [23]. CMs  were suspended with deionized water at a
concentration of 50 mg/ml. 50 l of the suspension was  dripped
on the collagen coated scaffold carefully, and then the scaffold was
dried and stored at −20 ◦C until use.
2.5. SEM observation of scaffolds
The lengths of HA scaffolds before and after sintering were mea-
sured to calculate the linear shrinkage. The pore size was  measured
using an inverted ﬂuorescence microscope. Five pores were ran-
domly selected in a ×10 view for each sample. The average length
of the pores was  calculated as the actual pore size. The microstruc-
tures of HA, HC and HCC scaffolds were observed by a Scanning
electron microscopy (SEM, S-2400; Hitachi, Japan).
2.6. In vitro drug release
In vitro release of rhBMP-2 from the HCC composite scaffolds
were carried out at 37 ◦C in 2 ml  of PBS. At pre-determined inter-
vals, the release medium was  withdrawn and renewed with a
fresh medium each time. The in vitro release kinetics of rhBMP-2
from HCC scaffolds was examined for 21 days. 2 ml PBS contain-
ing rhBMP-2 at 0.5, 1, 2, 4, 7, 14 and 21 days was all collected and
replaced with equal amount of fresh PBS. Samples were stored at
−20◦ C until the test. To determine the total amount of rhBMP-2 at
each scaffold, the microspheres on the scaffold were dissolved with
500 l of acetic acid (0.2 M),  and then the solution was diluted with
3.5 ml  PBS. All collected samples were centrifuged and ﬁltered to
remove the free ﬂoating microspheres and quantitatively analyzed
using a Human BMP2 ELISA Kit (Sigma-Aldrich Co., USA) at the end
of the experiment. The experiments were run in triplicate per time
point. Three scaffolds were measured here in total.
2.7. Cell viability
hMSCs (Third passage, ScienCell Research Laboratories, USA)
were incubated in Mesenchymal Stem Cell Medium (MSCM, Scien-
Cell Research Laboratories, USA) with Penicillin and Streptomycin
solution (Gibco inc., USA) as described by Li et. al. [24]. For cell seed-
ing, HA, HC and HCC scaffolds were sterilized under UV light for 2 h
and washed with PBS three times. hMSCs were seeded in a 96-well
plate at a density of 5000 cells/well. 200 l of MSCM was added to
each well. The sterilized HA, HC and HCC scaffold was  put into the
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ell, and the culture medium was changed every 3 days. The cells
ultured with MSCM without a scaffold were set as a control. On
ays 1, 3 and 7 of culture, three scaffolds were removed separately,
nd the cells were rinsed with PBS. CCK-8 reagent (Dongjindo
olecular Technologies, inc., Japan) was diluted with MSCM at a
atio of 1:10(v/v) and 100 l of the MSCM containing CCK-8 reagent
as added to each well. After 2 h of incubation at 37 ◦C, the optical
ensity of cell proliferation was measured with a microplate reader
t 450 nm.
.8. Immunoﬂuorescent assay
Concentration of hMSCs were adjust to 1 × 106 cells/ml. Fifty
icroliters of the MSCs were dipped on the HA, HC and HCC scaffold
espectively, and incubation in a 24-well plate for 30 min. Then
50 l of MSCM was added to each well. After incubated for 24
r 48 h, the media was gently removed and the specimens were
ashed with PBS. The cells on the scaffolds were ﬁxed with 4%
araformaldehyde (Gibco inc., USA) for 10 min. PBS was used to
ash the specimen at each subsequent steps. Triton(0.2%, w/v) was
sed to increase the permeabilization of the cells for 5 min, and
hen nonspeciﬁc binding was blocked by 1% BSA for 30 min. Anti-
-Tubulin Mouse Monoclonal Antibody (Abcam plc, UK) was  added
o combine with the cytoskeleton protein for 60 min. After washing
ith PBS for 3 times, the specimens were incubated with goat anti-
ouse IgG(Zhong Shan Golden Bridge Biotechnology, China). The
′,6-diamidino-2-phenylindole (DAPI) solution (Sigma-Aldrich Co.,
SA) was added to each well for 5 min  before the scaffolds were
bserved with the ﬂuorescence microscope.
.9. Alkaline phosphatase (ALP) activity
The ALP activity of hMSCs was used to determine the bioactiv-
ty of the released rhBMP-2. The HCC scaffolds were soaked in 5 ml
SCM for 1, 3 or 7 days, respectively. At each time point, the scaf-
old was removed, the culture medium was centrifuged and the
upernatant was collected after sterilization with a 0.22 m ﬁlter.
MSCs were seeded in a 96-well plate (10000 cells/well), and then
ncubated overnight. The culture medium was refreshed with the
ollected MSCM above or MSCM without rhBMP-2(control group).
he cells were washed with PBS and lysed in 0.2% Triton X–100 in
istilled water for 20 min  at room temperature after culturing for
 days. The ALP activity of each well was calculated using Quan-
iChrom TM Alkaline Phosphatase Assay Kit (BioAssay Systems,
SA). The absorbance was measured using microplate reader (Syn-
rgy H1) at 405 nm.  The ALP activity was normalized by the total
ntracellular protein production which was tested strictly accord-
ng to the instructions of Pierce BCA Protein Assay Kit (Thermo
cientiﬁc, USA).
.10. In vivo experiment
Animal experiments were approved by the animal ethics com-
ittee of Peking Union Medical College Hospital (PUMCH), China.
ll procedures were performed in accordance to speciﬁcations of
uidelines for the care and maintenance of animals. Twenty-four
ew Zealand rabbits (2.5 to 3.0 kg, Experimental Animal Center
f PUMCH, China), age 3 ∼ 6 months, were anesthetized with an
ntravenous injection of 3% pentobarbital sodium (1 ml/kg body
eight, Sigma, USA). A 2 cm skin incision from the groin mid-
oint to the knee was taken, and the myolemma  was  longitudinally
plit. After implanting scaffolds into the intramuscular gap, muscle
nd skin were sutured with 3–0 silk sutures. 800,000IU penicillin
odium (North China Pharmaceutical Group Corporation, China)
as injected intramuscularly before and after operation for 3 days
o prevent infection. 0.15 mg  buprenorphine (Tianjin Institute ofBiointerfaces 141 (2016) 491–498 493
Pharmaceutical Research, China) was  also applied to relieve pain
every 12 h for 3 days. Animals were sacriﬁced after 4 and 8 weeks
respectively (n = 4 × 3 × 2). Samples were removed and ﬁxed in 4%
paraformaldehyde.
2.11. Evaluation of bone regeneration capability
Three-dimensional images of bone regenerated in the scaf-
folds were visualized with the Micro-computed tomography (CT)
scans (SkyScan 1076, Belgium). Samples were scanned at a slice
interval of 9 m,  energy of 70 kV, and current of 139 A. The
2-dimensional images were acquired with the NRecon software
(Version 1.5, Bruker Corporation, USA) and analyzed with the CT
Analyser software (Version 1.8, Bruker Corporation, USA). Trabec-
ular thickness (Tb.Th), Bone volume (BV), and Bone volume/Tissue
volume (BV/TV) were calculated in the regions of interest (ROI) gen-
erated based on the scaffold margin. The thresholds of bone and HA
scaffold were set at 148–661 and 661–3040 respectively. At last,
they were reconstructed and submitted to the Mimics 10.0 software
(Materialise, Belgium) for processing to produce the 3-dimensional
images of bone regenerated.
2.12. Histological evaluations
The histological specimens were ﬁxed in 4% paraformaldehyde
for 7 days, dehydrated with ethyl alcohol, embedded in methyl-
methacrylate (MMA), and sectioned transversely at a thickness of
50 m with the Leica SP1600 saw microtome (Leica Biosystems,
German). The slides were stained with VanGieson for histological
evaluations. The bone formations in the scaffolds were observed
using a microscope and a digital camera (Leica Microsystems).
2.13. Ethics statement
All experiments involving the use of animals were in compliance
with Provisions and General Recommendation of Chinese Experi-
mental Animals Administration Legislation and were approved by
Beijing Municipal Science & Technology Commission (Permit Num-
ber: SCXK (Beijing) 2006-0008 and SYXK (Beijing) 2006-0025).
2.14. Statistical analysis
Data was expressed as mean ± standard deviation (SD). Samples
of each group were performed in triplicate. One-way ANOVA was
used to analyze the differences among groups. A P < 0.05 value was
considered as statistically different.
3. Results
3.1. Characteristics of scaffolds
As designed, porous HA scaffolds were successfully fabricated by
the combination of extrusion deposition technique and microwave
sintering. After sintering, the scaffold dimensions were reduced
from 15 × 7.4 × 5.5 mm3 to 10.5 × 5.2 × 3.85 mm3 (Fig. 1). The
shrinkage of the structure after sintering was about 34.4% in all
directions. The cross-section SEM image of HA scaffold illustrated
that the pores were interconnected with a diameter of approx-
imately 460 m.  In HC scaffolds, a thin layer of collagen was
uniformly adhered to HA surface to modify it. In HCC scaffolds,
scaffolds were successfully coated with 10 m spherical CMs  con-
taining rhBMP-2 by collagen.
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Fig. 1. Design drawing (15 × 7 × 5 mm
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pig. 2. rhBMP-2 release proﬁle of the HCC scaffold coating with rhBMP-2 micro-
pheres.
.2. Release proﬁle of rhBMP-2 in vitro
In vitro release of rhBMP-2 from the HCC scaffold was  carried out
n PBS buffer solution at 37 ◦C. To efﬁciently keep the therapeutic
ffect of rhBMP-2, it is crucial to ensure that pristine rhBMP-2 can
e released from the scaffold. Hydrazone bonds can be reversibly
leaved to aldehyde and hydrazine groups under a weakly acidic
nvironment. Since rhBMP-2 contains a hydrazine group, a hydra-
one bond is a suitable linker to covalently conjugate rhBMP-2 to
A-collagen. When the hydrazone bone was broken, rhBMP-2 can
e gradually released from the HCC scaffold. The average amount of
hBMP-2 in the scaffolds was 3.63 ± 0.24 g measured by dissolv-
ng with acetic acid. Fig. 2 shows the kinetic release of rhBMP-2
n vitro. The release of rhBMP-2 had a unique biphasic proﬁle of
n initial burst release (phase I) in the ﬁrst seven days and a sec-
ndary sustained release (phase II) after that. Total of 1.98 ± 0.17 g
54%) was continuously released from the HCC scaffold during 21
ays. Approximately 50% of rhBMP-2 was cumulatively released in
hase I, and then the release rate was gradually decreased with3) and SEM images of scaffolds.
time. During 21days, the concentration of released rhBMP-2 was
above 112.8 ng/ml at each tested time point. These results verify
that chemical conjugation of rhBMP-2 to polymeric CS microsphere
can efﬁciently avoid initial burst release and enhance long-term
drug release in a controlled manner. The long-term controlled drug
release should beneﬁt from long degradation time of CS and the
resulted weakly acidic compartment after CS microspheres degra-
dation. So the drug delivery system based on the scaffold meets the
demand of long-term drug treatment for bone defects.
3.3. Cell viability
The hMSCs proliferation results on days 1, 3 and 7 determined
by CCK-8 assay are shown in Fig. 3. The results show that all three
scaffolds are conducive to cell duplication with no signiﬁcant dif-
ference (p > 0.05) on days 1, 3 and 7 of culture. There were more
cells in the scaffolds with time. The morphology and proliferation
of hMSCs that adhere to the surface of the scaffolds are shown in
Fig. 4. The numbers of cells stained with DAPI on the surfaces of
HC and HCC scaffolds were more than that of HA scaffolds after 24
and 48 h of culture, especially for HCC scaffolds. hMSCs extended
their pseudopodia to closely cling to the surface in the HCC scaffold
by -tubulin staining. Based on these results, it could be seen that
collagen and CMs  were favorable for cell adhesion and expansion.
3.4. ALP activity
ALP activity was measured as a marker of osteogenic differenti-
ation for hMSCs. As shown in Fig. 3, the leaching solution of the HCC
scaffold could enhance the ALP activity as compared to control, and
it increased with increasing culture time.
3.5. Ectopic bone formation
Besides evaluating drug release, the capability of bone regenera-
tion was  also investigated simultaneously when the scaffolds were
implanted intramuscularly. Bone defect regeneration capability of
the composite scaffolds was evaluated by X-ray microradiography
and histological analysis. The results of CT showed the newly
ectopic bone formation in scaffolds was  signiﬁcantly enhanced
H. Wang et al. / Colloids and Surfaces B: Biointerfaces 141 (2016) 491–498 495
Fig. 3. Results of hMSCs culture: proliferation results of hMSCs co-culture in scaffolds & ALP activity results of hMSCs co-culture with the leaching solution of the HCC
scaffolds (set control = 1).
Fig. 4. Fluorescence microscope images of hMSCs stained with DAPI and/or -Tubulin on the surfaces of the HA, HC and HCC scaffolds.
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Table 1
The quantitative analysis results of CT for HCC scaffolds.
4 weeks 8 weeks P
BV (mm3) 4.69 ± 1.09 7.12 ± 1.56 0.04Fig. 5. CT results of HCC scaffolds after implanting for 4 and 8 weeks.fter coating of rhBMP-2CMs in HCC scaffolds compared to HA and
C scaffolds (Fig. 5). Further quantitative analysis with CT showed
b.Th, BV, and BV/TV of HCC scaffolds were all increasing with time
Table 1). They were conﬁrmed by the histological results (Fig. 6).BV/TV (%) 11.56 ± 1.22 17.14 ± 2.26 0.01
Tb.Th(mm) 0.074 ± 0.05 0.083 ± 0.05 0.04
It showed that ectopic bone formation was  induced by sustained
delivery of rhBMP-2 compared to no delivery. No bone formation
with only ﬁbrous tissues was observed in HA and HC scaffolds after
4 and 8 weeks. In contrast, the implantation of rhBMP-2CMs coated
HA (HCC) scaffolds resulted in extensive bone formation, with a
lot of osseous/osteoid tissue. Osseous tissue was located around
the pores with osteoid tissue in the center. The results from X-ray
microradiography and histological analysis robustly illustrated that
the rhBMP-2-loaded scaffold also possesses excellent bone regen-
eration capability.4. Discussion
In bone tissue engineering, there are three elements including
scaffold, factors and seeding cells, where the scaffold is the most
496 H. Wang et al. / Colloids and Surfaces B: Biointerfaces 141 (2016) 491–498
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asic one. Traditional scaffolds cannot be adapted to the exact shape
f the individual osseous defect [4]. Their microstructure includ-
ng pore size, porosity, connectivity and pore shape affects the
ngrowth of bone tissue and the mechanical property of the scaf-
old [25]. However, they are not able to be accurately controlled by
raditional methods [26]. Using computer-assisted 3-D printing, an
merging RP technique, individual shaped 3-D ceramic scaffolds
an be tailored with precise dimensions and highly deﬁned and
egular internal characteristics. Pure HA is one of the best materi-
ls for regeneration of new bone [27]. Previously, a more soluble HA
eramic scaffold has been fabricated by extrusion deposition tech-
ique and microwave sintering techniques [14]. As shown in Fig. 1,
hese porous HA scaffolds possessed good inner/outer architecture,
nd interconnective pores for bone ingrowth, although they had a
ertain degree of shrinkage after sintering.
The osteoinductivity of this porous HA scaffold should be
nhanced, although the biocompatibility and osteocondutivity had
een conﬁrmed before [14]. BMPs are bone growth factors synthe-
ized and secreted by osteoblasts, and can induce differentiation
f mesenchymal cells into osteoblasts, stimulating osteogenesis
n remodeling and healing processes [28]. It has been reported
hat rhBMP-2 and rhBMP-7 have the satisfactory osteoinductivened with VanGieson after implanting for 4 and 8 weeks.
property. Thus, introduction of rhBMP-2 to this scaffold would
probably facilitate the scaffold with osteoinductivity, and enhanced
the ingrowth of bone tissue.
A controlled and localized delivery system for a small amount
of rhBMP-2 should be fabricated, because rhBMP-2 is rapidly
degraded with a short half-life (7–16 min) in vivo [29]. To over-
come this, an excess dosage of rhBMP-2 is an alternative, but it
is expensive and can cause undesirable side-effects [30]. In this
study, rhBMP-2CMs of 10–20 m were successfully prepared via
an emulsion cross-linking method as a potential drug/protein deliv-
ery system. After coating to HA surface by collagen, they showed a
controlled delivery of rhBMP-2 in HCC scaffolds. Every HCC scaffold
contained only 3.63 ± 0.24 g rhBMP-2, much less than the dosage
recommended by Medtronic. rhBMP-2 could release from the HCC
scaffold continuously for over 21 days in vitro, and even then, the
concentration of released rhBMP-2 (112.8 ng/ml) was still higher
than the minimum concentration (10 ng/ml) which could upregu-
late osteogenesis of MSCs [31]. Therefore, CMs/Collagen/HA was a
suitable delivery system for rhBMP-2.
The release kinetic of rhBMP-2 in this study showed a unique
biphasic proﬁle of an initial burst release (phase I) and a secondary
sustained release (phase II). It was speculated that phase I was
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[
[
[
[
[H. Wang et al. / Colloids and Surfac
ainly derived from the direct diffusion of rhBMP-2 in CMs  and
he release in phase II was most likely attributed to the diffusion
hrough collagen. Initially, a sustained release was  thought to be
t for inducing osseous formation [32]. Recent studies conﬁrmed
hat a transient burst release followed by a sustained release could
e even better than a continuously sustained release [33–36]. The
urst release could possibly correlate with the retaining and induc-
ng of host cells to the scaffolds and the sustained release might
ave the function to coordinate distribution of cells inside the scaf-
olds [36]. It was consistent with the biphasic proﬁle of BMP-2
uring the healing process of bone fracture in vivo [37]. The unique
iphasic release proﬁle of rhBMP-2/CMs/Collagen are favorable for
one formation in porous HA scaffolds.
No material, including rhBMP-2, collagen, and chitosan, could
nﬂuence the cell viability of the MSCs [31,38]. That is why there
as no signiﬁcant difference in cell proliferation among these three
roups and the number of cells increased with culture time. As
xpected, coating porous HA scaffolds with a collagen layer favored
dhesion and growth of hMSCs. Collagen as a primary protein of
one tissue had excellent cell adhesion, biodegradability and bio-
ompatibility [39]. It is an effective method to enhance the adhesion
f cells to scaffolds by coating with collagen [40]. Hence, the num-
er of cells attaching on the surface of HA scaffolds was less than
he two others. More cells adhering on the HCC surface might be
ssociated with more roughness of HCC scaffolds by CMs  coating.
he suitable attachment of hMSCs is a prerequisite of a successful
issue engineering [41].
The hypothesis of this study was that rhBMP-2 controlled
elease made porous HA scaffolds with osteoinductivity. To verify
t, the differentiation ability of the released rhBMP-2 was measured
n vitro using hMSCs. ALP, an ectoenzyme produced by osteoblasts,
as selected as a maker to verify the osteogenic differentiation.
he result suggested that the released rhBMP-2 still retained its
ioactivity after encapsulating into CMs/collagen/HA scaffold, and
he ALP activity was continuously elevated. It was closely related
o the release proﬁle of rhBMP-2 in vitro because the osteoinduc-
ivity of rhBMP-2 was in a dose-dependent manner [31]. In the ﬁrst
 days, the cumulative amount of released rhBMP-2 kept rising.
To further conﬁrm the hypothesis, an experiment of ectopic
one formation in vivo was performed in this study. Scaffolds of
hree different types (HA, HC and HCC) were implanted intramus-
ularly respectively for 4 or 8 weeks. As shown in the results of CT
nd histological slices, new bone tissue could be observed alone in
he rhBMP-2-loaded scaffolds (HCC). The bone regeneration effect
as observed in week 4, and continuously increased until 8weeks
y quantitative analysis of CT. Because only rhBMP-2 had the
nique property of ectopic bone formation [42]. Histological results
howed that osseous tissue was in the periphery of the pores, and
steoid tissue was in the center of the pores. It suggested that newly
egenerated bone was induced by rhBMP-2 released from CMs  on
he surface of scaffolds.
. Conclusions
The morphology, structure and mechanical property of the scaf-
old were rationally designed and tailored to be favorable for
ong-term drug controlled release and bone regeneration. In this
tudy, a 3D printed porous HA scaffold with embedded rhBMP-2-
elivery microspheres to improve cell differentiation capabilities
as developed. The cytological assay indicated that the composite
ystem possesses a good cell biocompatibility and osteoinductivity
o induce osteogenic differentiation of hMSCs in vitro. The in vitro
rug release experiment showed that rhBMP-2 could be released
radually from the composite for more than 21 days. In addition,
n vivo experiment showed that the scaffold also works well to
[Biointerfaces 141 (2016) 491–498 497
repaire bone defects. These results demonstrate the composite scaf-
fold drug delivery system can simultaneously achieve localized
long-term drug controlled release and bone regeneration, which
is promising for the reconstruction of complex bony defects.
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